Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC1A3 contributes to L‐asparaginase resistance in solid tumors

16 Sept 2019

Abstract excerpt

L-asparaginase (ASNase) serves as an effective drug for adolescent acute lymphoblastic leukemia. However, many clinical trials indicated severe ASNase toxicity in patients with solid tumors, with resistant mechanisms not well understood. Here, we took a functional genetic approach and identified SLC1A3 as a novel contributor to ASNase resistance in cancer cells. In combination with ASNase, SLC1A3 inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to DNA Repair Mechanisms
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31523835
DOI: 10.15252/embj.2019102147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC1A3 contributes to L‐asparaginase resistance in solid tumorsPMID 31523835Read ↗

A clinically attainable dose of L‐asparaginase targets glutamine addiction in lymphoid cell linesSemantic proximity Read ↗

Asparagine: A Metabolite to Be Targeted in CancersSemantic proximity Read ↗

Targeting Asparagine Metabolism in Solid TumorsSemantic proximity Read ↗

Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanismsSemantic proximity Read ↗

Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemiaSemantic proximity Read ↗

Drivers of de novo Serine/Glycine synthesis in acute leukemia.Semantic proximity Read ↗

Therapeutic Assessment of Targeting ASNS Combined with l -Asparaginase Treatment in Solid Tumors and Investigation of Resistance MechanismsSemantic proximity Read ↗

Asparagine synthetase: Function, structure, and role in disease.Semantic proximity Read ↗

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

An Asp to Strike Out Cancer? Therapeutic Possibilities Arising from Aspartate’s Emerging Roles in Cell Proliferation and SurvivalSemantic proximity Read ↗

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid MalignanciesSemantic proximity Read ↗

PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to l-asparaginaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.